Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues

Simple item page
dc.contributor.authorvan der Spuy, Z M
dc.contributor.authorWood, M
dc.contributor.authorFieggen, G
dc.contributor.authorHendricks, M
dc.date.accessioned2021-10-08T07:17:51Z
dc.date.available2021-10-08T07:17:51Z
dc.date.issued1993
dc.description.abstractWe assessed the possible role of CA 125 in the monitoring of gonadotrophin-releasing hormone (GnRH) agonist analogue therapy in women with endometriosis and uterine fibroids. Serum concentrations of this cell surface antigen did not correlate with uterine volume and appeared to have no value in the assessment of shrinkage of uterine fibroids during GnRH agonist treatment. While CA 125 levels were not always elevated in subjects with endometriosis, they fell during treatment in all patients. The change accurately reflected therapeutic progress in these women and was of particular value in those patients who had commenced therapy with elevated levels. It is suggested that CA 125 may be useful in the monitoring of therapeutic progress in selected patients with endometriosis treated with GnRH agonists; the need for surgical follow-up may be obviated.
dc.identifier.apacitationvan der Spuy, Z. M., Wood, M., Fieggen, G., & Hendricks, M. (1993). Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. <i>South African Medical Journal</i>, 83(7), 510 - 513. http://hdl.handle.net/11427/34841en_ZA
dc.identifier.chicagocitationvan der Spuy, Z M, M Wood, G Fieggen, and M Hendricks "Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues." <i>South African Medical Journal</i> 83, 7. (1993): 510 - 513. http://hdl.handle.net/11427/34841en_ZA
dc.identifier.citationvan der Spuy, Z.M., Wood, M., Fieggen, G. & Hendricks, M. 1993. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. <i>South African Medical Journal.</i> 83(7):510 - 513. http://hdl.handle.net/11427/34841en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - van der Spuy, Z M AU - Wood, M AU - Fieggen, G AU - Hendricks, M AB - We assessed the possible role of CA 125 in the monitoring of gonadotrophin-releasing hormone (GnRH) agonist analogue therapy in women with endometriosis and uterine fibroids. Serum concentrations of this cell surface antigen did not correlate with uterine volume and appeared to have no value in the assessment of shrinkage of uterine fibroids during GnRH agonist treatment. While CA 125 levels were not always elevated in subjects with endometriosis, they fell during treatment in all patients. The change accurately reflected therapeutic progress in these women and was of particular value in those patients who had commenced therapy with elevated levels. It is suggested that CA 125 may be useful in the monitoring of therapeutic progress in selected patients with endometriosis treated with GnRH agonists; the need for surgical follow-up may be obviated. DA - 1993 DB - OpenUCT DP - University of Cape Town IS - 7 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 1993 SM - 0038-2469 T1 - Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues TI - Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues UR - http://hdl.handle.net/11427/34841 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34841
dc.identifier.vancouvercitationvan der Spuy ZM, Wood M, Fieggen G, Hendricks M. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues. South African Medical Journal. 1993;83(7):510 - 513. http://hdl.handle.net/11427/34841.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Obstetrics and Gynaecology
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue7
dc.source.journalvolume83
dc.source.pagination510 - 513
dc.source.urihttps://dx.doi.org/10.7196/sajs.718
dc.subject.otherAntigens, Tumor-Associated, Carbohydrate
dc.subject.otherEndometriosis
dc.subject.otherFemale
dc.subject.otherGonadotropin-Releasing Hormone
dc.subject.otherHumans
dc.subject.otherLeiomyoma
dc.subject.otherUterine Neoplasms
dc.subject.otherAntigens, Tumor-Associated, Carbohydrate
dc.subject.otherGonadotropin-Releasing Hormone
dc.titleSerum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vanderSpuyZM_Serum_CA_125_co_1993.pdf
Size:
2.61 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles